Cancer Research ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
| | | | Charities in the UK fund more cancer research than the government, meaning funding is heavily reliant on donations from our supporters. These should be a top-up rather than a replacement for robust government-funded research.
The UK could be facing a more than £1 billion funding gap into cancer research over the next decade, if funding does not keep pace with inflation and increases in cancer cases.
A general election is coming soon. When it comes, it must be a turning point for people affected by cancer.
The UK needs a renewed focus on research investment, so that promising research can be supported. In our manifesto, Longer, better lives, we’ve called for sustainable biomedical research funding; an effective clinical trials environment; and incentives for industry to invest in and develop new products in the UK.
Help us close the funding gap and make life-saving research a political priority. Join us in telling party leaders to back our calls for longer, better lives.
|
| | |
| | |
|
|
|
|
Funding & Research Opportunities |
| Get in touch with our office for confidential advice on eligibility, remit and funding options prior to applying. |
|
| | | | | | | | | | | | Applications accepted all year round |
|
|---|
| | | | | | Applications accepted all year round |
|
|---|
| | | | | | Applications accepted all year round |
|
|---|
| | | | | | Applications accepted all year round |
|
|---|
|
| | |
|
|
Nature: Mutational signature points to unknown exposure underlying geographical variation in kidney cancer rates |
| Scientists from Cancer Grand Challenges team Mutographs sequenced 962 clear cell renal cell carcinomas from 11 countries across four continents, identifying a new mutational signature which partially explains the variation in incidence across the world. The signature was found in all countries, with mutation load correlating with global incidence rates. Further work will be needed to determine what the mutagenic agent responsible for SBS40b is, and whether this signature is causal in cancer development.
Read more about the background, including how these findings contrast with the team's previous work, SBS40b and the other signatures they uncovered, what we still don’t know, as well as the team members who drove the work.
|
| | |
|
|
|
| | | | | All cancer postdocs are invited to join our Postdoc Futures event in Manchester on 7 June.
The highly interactive sessions will help you better understand the broad professional value of postdoctoral experience, gain knowledge about the career development process, and provide strategies you can use to identify opportunities in different sectors.
You’ll also hear about the funding, training and support we offer to postdocs, including an update on a new programme for those planning to transition to an independent academic position.
This is a free event, you will be charged a holding fee upon booking which will be refunded in full after you attend (excluding the Eventbrite fee). | | |
| | | | | | | Early career researcher Giulia Biffi – a Junior Group leader at the Cancer Research UK Cambridge Institute – has been making her mark in the field of pancreatic cancer. Her work is raising new questions about cancer-associated fibroblasts (CAFs) and their potential to offer new therapeutic opportunities for patients.
During her postdoc, Giulia published clear evidence of how CAFs in pancreatic cancer have very distinct features and potential functions. Since then, Giulia and her lab have continued to discover more about this complexity, revealing new insights into a subset of myofibroblast CAFs that are considered to be tumour-restricting, but are actually metastasis-promoting.
We spoke to Giulia about her passion for pancreatic cancer research and what’s next.
| | |
|
|---|
|
|
|
|
| | A role for surrogate endpoints in future cancer screening trials |
| | What are the requirements/ considerations for identifying an endpoint that can be measured earlier than disease-specific mortality and that could serve as the primary outcome?
“We need to consider the potential in using surrogates to accelerate the translational pathway where appropriate. We can stop trials of ineffective screening early and progress implementation research of promising screening strategies while awaiting cancer mortality results”, says Alexis Webb, a Research Programme Manager at Cancer Research UK.
In a recent publication in Lancet Oncology, Alexis and colleagues present the current landscape and challenges of using surrogate endpoints for cancer screening trials.
The authors also provide a framework that researchers can use when exploring the possibility of using surrogate endpoints. |
| | |
|
|
|---|
|
|
|
|
|
| | | | | Are you interested in presenting your latest research to the international brain tumour community? The deadline for abstract submission is approaching fast, so don't miss the chance to share your work with experts in the field.
Submit an abstract under one of the conference themes to be considered for a short talk or poster presentation and get valuable feedback on your research. We're also offering limited travel and accommodation bursaries to early-career researchers whose abstracts are accepted.
The submission deadline is 24 May. | | |
| | | | | | | On day 1 at our Cancer Prevention Research Conference, Salvatore Vaccarella (International Agency for Research on Cancer) and Chanita Hughes-Halbert (USC Norris Comprehensive Cancer Center) will be chairing a session on health inequities and prevention.
Join us to hear from Ophira Ginsburg (NCI), Tiffany Carson (Moffitt Cancer Center) and Samilia Obeng-Gyasi (The Ohio State University) highlighting the importance of preventative interventions to reduce inequities in cancer incidence and avoid any further exacerbation.
Grab your tickets for our conference in Boston from 25-27 June. | | |
|
|---|
|
|
|
|
What did you think of this email? |
|
| | |
|
|
| | Together we are
beating cancer |
| | |
|---|
|
|
|
| | | You are playing a crucial role in helping us beat cancer sooner, so we'd like to continue to keep you updated on what we're up to. You can manage your preferences and unsubscribe here.
Your details are safe with us. Check out our Privacy Policy.
Our supporters are at the heart of everything we achieve at Cancer Research UK. Read our Fundraising Promise.
This email is from Cancer Research UK. Cancer Research UK is a registered charity in England and Wales (1089464), Scotland (SC041666), the Isle of Man (1103) and Jersey (247). A company limited by guarantee. Registered company in England and Wales (4325234) and the Isle of Man (5713F). Registered address: 2 Redman Place, London, E20 1JQ. |
|
|
|
